NasdaqGM - Delayed Quote USD

SL Science Holding Limited (SLBT)

0.9375 +0.0374 (+4.16%)

At close: November 6 at 4:00:00 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

SL Science Holding Limited Reports First Half 2026 Financial Results

GlobeNewswire 12d ago

SLBT
+4.16%
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

GlobeNewswire 1mo ago

SLBT
+4.16%
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

GlobeNewswire 2mo ago

SLBT
+4.16%
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall

Simply Wall St. 2mo ago

SLBT
+4.16%
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

GlobeNewswire 2mo ago

SLBT
+4.16%
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

GlobeNewswire 3mo ago

SLBT
+4.16%
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

GlobeNewswire 3mo ago

SLBT
+4.16%
Top Midday Decliners

PREMIUM
MT Newswires 4mo ago

SPCE

GOOGL

SLBT
+4.16%
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

GlobeNewswire 2mo ago

SLBT
+4.16%
SL Science Holding Limited Reports Full Year 2025 Financial Results

GlobeNewswire 4mo ago

SLBT
+4.16%
Sector Update: Healthcare Stocks Decline Late Afternoon

PREMIUM
MT Newswires 3mo ago

BLCO

PFE

XLV

Performance Overview

Return	SLBT	S&P 500 (^GSPC)
YTD	-91.11%	+7.76%
1-Year	-90.98%	+9.77%
3-Year	-90.70%	+68.96%

U.S. markets closed

SL Science Holding Limited (SLBT)

SL Science Holding Limited Reports First Half 2026 Financial Results

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Top Midday Decliners

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Holding Limited Reports Full Year 2025 Financial Results

Sector Update: Healthcare Stocks Decline Late Afternoon